Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients

We retrospectively analyzed efficacy and safety of therapy with rabbit antithymocyte globulin (rATG) in combination with cyclosporine A (CsA) in 30 Japanese adult patients with acquired aplastic anemia (AA) in the Kyoto Clinical Hematology Study Group. The median observation period was 31months and the median age of the patients was 54years. The objective response rates (ORRs) to rATG plus CsA increased over time until 18months after the start of treatment; the rate of achievement of better than partial response at 18months was 66.7%. The 2-year overall survival (OS) rate was 79% in all patients. In eight patients aged 75years old, the ORR was 62.5% and the 2-year OS rate of 50% was not significantly inferior to that in patients aged 74years old. The overall mortality rate was 16.7% in our cohort, while the mortality rate in patients aged 75years old was 37.5%, which was higher than that in patients aged 74years old (9.1%), although the difference was not statistically significant. Collectively, rATG combined with CsA is an effective and feasible treatment for AA, while patients should be appropriately selected.